Wednesday, June 03, 2015 7:09:30 AM
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapeutics, primarily in the areas of dermatology and ophthalmology, today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) on its novel, self-delivering RNAi platform (sd-rxRNA®). The patent, titled "RNA Interference in Ocular Indications," covers methods of use of RXi's VEGF-targeting and CTGF-targeting self-delivering rxRNAs®, including RXI-109, for use in the eye. The patent, once issued, will be scheduled to expire in 2031.
Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
This core patent, within RXi's intellectual property portfolio, broadens the coverage of RXi's self-delivering platform and provides coverage of RXI-109 for the treatment of ocular fibrosis. Scarring of the eye, as a consequence of disease or injury, can result in impairment or loss of vision. Medical or surgical treatments for the scarring component of ocular indications is limited. A therapeutic, such as RXI-109, that is effective in reducing the activity of CTGF could have great benefit for patients whose ocular condition has an active scarring component. To date, there are no FDA-approved therapeutics for the treatment and prevention of scarring in the eye.
"We are pleased to receive this notice of allowance from the USPTO, covering the use of our proprietary VEGF and CTGF-targeting sd-rxRNAs in the eye, as RXi prepares to file an IND for the use of RXI-109 to treat ocular fibrosis," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He further added, "The Company continues to advance its clinical programs as planned and we look forward to providing additional updates on our ophthalmology and dermatology programs in the coming months."
Recent PHIO News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2024 09:00:13 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/20/2024 09:03:23 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 05/20/2024 08:59:26 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/17/2024 08:45:23 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/17/2024 01:04:34 PM
- Phio Pharmaceuticals Secures New Investor • GlobeNewswire Inc. • 05/17/2024 01:00:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 01:00:13 PM
- Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID) • GlobeNewswire Inc. • 05/16/2024 12:00:00 PM
- Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study • GlobeNewswire Inc. • 05/15/2024 05:00:00 PM
- Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 09:25:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 09:23:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 09:20:56 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/08/2024 09:04:03 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/08/2024 09:02:05 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/08/2024 09:00:34 PM
- Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO) • GlobeNewswire Inc. • 04/30/2024 11:30:00 AM
- Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells • GlobeNewswire Inc. • 04/22/2024 05:10:09 PM
- Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID) • GlobeNewswire Inc. • 04/16/2024 11:30:00 AM
- Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT) • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- National Spotlight Features Phio’s Innovative RNAi Technology Platform • GlobeNewswire Inc. • 04/03/2024 11:30:00 AM
- Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update • GlobeNewswire Inc. • 04/02/2024 11:30:00 AM
- Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies • GlobeNewswire Inc. • 03/21/2024 11:30:00 AM
- Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research • GlobeNewswire Inc. • 03/13/2024 06:00:25 PM
PickleJar Debuts Nationwide Contest With Brian Kelley for Fans to Win a Three-Day Bahama Cruise • NREG • Jun 3, 2024 8:45 AM
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM